In vitro BRAF V600E NSCLC cell lines as a resistance mechanism to osimertinib showed sensitivity to an association with osimertinib and a BRAF inhibitor (encorafenib) [128]. This evidence concerns the gene BRAF and non-small cell lung carcinoma.